Duration of Penpulimab: although the mean elimination half-life of penpulimab is 23.3 d, anti-PD-1 therapy generates polyclonal and memory-adaptive antitumor immunity that can control disease heterogeneity and reset tumor-host immune interactions to cancer rejection (25, 26). Here, PDCD1 is linked to neoplasm.